We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Research breakthrough to treat female-specific epilepsy
News

Research breakthrough to treat female-specific epilepsy

Research breakthrough to treat female-specific epilepsy
News

Research breakthrough to treat female-specific epilepsy

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Research breakthrough to treat female-specific epilepsy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

An international team, led by a University of Adelaide genetics expert, has made a breakthrough discovery which is expected to help thousands of young girls worldwide who are suffering from a rare yet debilitating form of epilepsy.


Professor Jozef Gecz, from the University of Adelaide's Robinson Research Institute, was a key player in identifying the responsible gene and mutations in this female-only epileptic syndrome, in 2008.


In breakthrough research published in Oxford Journals, Human Molecular Genetics, Professor Gecz has now found a treatment for this disorder.


A United States pharmaceutical company Marinus Pharmaceuticals is now recruiting affected girls as part of the world's first clinical trial to test the therapy.


Professor Gecz says this condition is unique as it presents almost exclusively in girls while boys with mutations in the gene are not affected.


"We discovered that this condition is caused by an inherited mutation of the protocadherin 19 (PCDH19) gene, located on the X-chromosome," says Professor Gecz, Head of Neurogenetics at the University of Adelaide. "And interestingly, both males and females can be born with this mutation but only females suffer from the symptoms of the condition.


"The girls are affected because they have two X-chromosomes, one healthy and one with the PCDH19 mutation, which would usually protect them from a X-chromosome borne disease, but in this case it drives the disorder," he says.


Professor Gecz has worked with the families of girls with this female-only epilepsy from all over the world and says while the condition affects everyone differently, in most cases it is highly incapacitating.


"This form of epilepsy affects 15,000-30,000 girls in the US and approximately 1000 in Australia," says Professor Gecz.


"Girls born with this gene mutation appear perfectly normal in the first few months of their lives but when they reach about eight months of age, they start suffering from debilitating and frequent seizures. The girls also commonly suffer from intellectual disability and autism -- it's a truly terrible disease which impacts the whole family.


"Through our current research we found that sufferers are deficient in a hormone called allopregnanolone.


"We know that hormones play a critical role in this condition because the seizures often stop once the girls reach puberty -- however the autism and intellectual disability remain. We expect that the longer we can delay the onset of seizures, the less the sufferer might be affected by the autism and intellectual disability.


"These finding are so promising that Marinus Pharmaceuticals has commenced a clinical trial to test the effect of a synthetic form of the neurosteroid allopregnanolone, called ganaxolone," he says.


Note: Material may have been edited for length and content. For further information, please contact the cited source.

The University of Adelaide   press release


Publication

Gecz J et al. Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency.   Human Molecular Genetics, Published Online June 29 2015. doi: 10.1093/hmg/ddv245


Advertisement